NEW YORK, April 19, 2026 /PRNewswire/ -- Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by Medtronic, one of the world's largest medical technology companies, alongside continued support from existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures. Pulnovo also welcomes new investors, including HSG (formerly Sequoia China), and other prominent global investors. This financing represents a significant milestone in Pulnovo's global growth trajectory and reflects strong validation from leading strategic and institutional investors of the company's technology, clinical progress, and long-term vision.

Separately, Medtronic and Pulnovo have entered into a commercial agreement that contemplates potential future commercialization opportunities. The agreement is designed to leverage the commercial synergy between Pulnovo and Medtronic and Medtronic's unique and extensive global commercialization capabilities.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Post a comment
Stop watching this discussion.